Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.
暂无分享,去创建一个
J. Miners | R. Mckinnon | M. Sorich | Paul A. Smith | Paul A Smith | Michael J Sorich | Ross A McKinnon | John O Miners
[1] P. Sprague. Automated chemical hypothesis generation and database searching with Catalyst , 1995 .
[2] David J. Livingstone,et al. The Characterization of Chemical Structures Using Molecular Properties. A Survey , 2000, J. Chem. Inf. Comput. Sci..
[3] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[4] G. Klebe,et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.
[5] K H Kim,et al. Quantitative structure-activity relationships of the metabolism of drugs by uridine diphosphate glucuronosyltransferase. , 1991, Journal of pharmaceutical sciences.
[6] S. Ekins,et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.
[7] Martyn G. Ford,et al. Unsupervised Forward Selection: A Method for Eliminating Redundant Variables , 2000, J. Chem. Inf. Comput. Sci..
[8] J. Crawford,et al. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. , 1991, The Journal of biological chemistry.
[9] B. Burchell,et al. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. , 1994, The Biochemical journal.
[10] W. Richards,et al. Self-organizing molecular field analysis: a tool for structure-activity studies. , 1999, Journal of medicinal chemistry.
[11] M. Green,et al. Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[12] S. Ekins,et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.
[13] J. Miners,et al. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. , 2002, Toxicology.
[14] S. Wold,et al. The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .
[15] S. Ekins,et al. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[16] J. Miners,et al. Drug glucuronidation in humans. , 1991, Pharmacology & therapeutics.
[17] G Klebe,et al. Docking ligands onto binding site representations derived from proteins built by homology modelling. , 2001, Journal of molecular biology.
[18] S. Ghosh,et al. Genetic lesions of bilirubin uridine‐diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler‐Najjar and Gilbert syndromes: Correlation of genotype to phenotype , 2000, Human mutation.
[19] P. Mackenzie,et al. Structural and functional studies of UDP-glucuronosyltransferases. , 1999, Drug metabolism reviews.
[20] D W Nebert,et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.
[21] S. Ekins,et al. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.
[22] E Holmes,et al. Quantitative structure-metabolism relationships (QSMR) using computational chemistry: pattern recognition analysis and statistical prediction of phase II conjugation reactions of substituted benzoic acids in the rat. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[23] R. Green,et al. Mechanism of indinavir-induced hyperbilirubinemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] T. Spector,et al. Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. , 1991, Biochemical pharmacology.
[25] M. Green,et al. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. , 1996, Archives of biochemistry and biophysics.
[26] A. Karim. The pharmacokinetics of Norpace. , 1975, Angiology.
[27] H. Saka,et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.
[28] C. Ioannides,et al. An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation. , 1998, Drug metabolism reviews.
[29] INHIBITION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE : A COMPARATIVE MOLECULAR FIELD ANALYSIS (COMFA) , 1996 .
[30] T. Visser,et al. Glucuronidation of thyroid hormone by human bilirubin and phenol UDP‐glucuronyltransferase isoenzymes , 1993, FEBS letters.
[31] B. Burchell,et al. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. , 1993, Molecular pharmacology.
[32] A. Good,et al. Structure-activity relationships from molecular similarity matrices. , 1993, Journal of medicinal chemistry.
[33] Roberto Todeschini,et al. Handbook of Molecular Descriptors , 2002 .
[34] J. Miners,et al. Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. , 1988, Biochemical pharmacology.
[35] Andrew Smellie,et al. Identification of Common Functional Configurations Among Molecules , 1996, J. Chem. Inf. Comput. Sci..
[36] M. Ratain,et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.
[37] J. Jones,et al. Mechanistic studies of uridine diphosphate glucuronosyltransferase. , 1994, Chemico-biological interactions.
[38] H. Kubinyi. Comparative Molecular Field Analysis (CoMFA) , 2002 .
[39] R. Tukey,et al. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.
[40] A. Cohen,et al. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome). , 1989, British journal of clinical pharmacology.